Increased bioavailability of oral melatonin after fluvoxamine coadministration

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 1, 2000, Pages 1-6

  Härtter, Sebastian ^a   Grözinger, Michael ^b   Weigmann, Harald ^b   Röschke, Joachim ^b   Hiemke, Christoph ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUVOXAMINE; MELATONIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0033964363     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104071     Document Type: Article

References (34)

1. 1. Utiger RD. Melatonin - the hormone of darkness. N Engl J Med 1992;327:1377-9.
2. 2. Reppert SM, Weaver DR. Melatonin madness. Cell 1995;83:1059-62.
3. 3. Waldhauser F, Waldhauser M. Melatonin and aging. In: Miles A, Philbrick DRS, Thompson C, editors. Melatonin: clinical perspectives. Oxford: University Press; 1998. p. 174-89.
4. 4. Petrie K, Dawson AG, Thompson L, Brook R. A double-blind trial of melatonin as a treatment for jet lag in international cabin crew. Biol Psychiatry 1993;33:526-30.
5. 5. Arendt J. Clinical perspectives for melatonin and its agonists. Biol Psychiatry 1994;35:1-2.
6. 6. Zhdanova IV, Wurtmann RJ, Morabito C, Riotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans. Sleep 1996;19:423-31.
7. 7. Wurtmann RJ. Introduction: Melatonin in humans. J Neural Transm 1986;21(suppl):1-8.
8. 8. Follenius M, Weibel L, Brandenberger G. Distinct modes of melatonin secretion in normal men. J Pineal Res 1995;18:135-140.
9. 9. Maurizi CP. The mystery of Alzheimer's disease and its prevention by melatonin. Med Hypotheses 1995;45:339-40.
10. 10. Falkson G, Falkson HC, Steyn ME, Rapoport BL, Meyer BJ. Plasma melatonin in patients with breast cancer. Oncology 1990;47:401-5.
11. 11. Calvo JR, Rafii-El-Idrissi M, Pozo D, Guerrero JM. Immunomodulatory role of melatonin: specific binding sites in human and rodent lymphoid cells. J Pineal Res 1995;18:119-26.
12. 12. Sandyk R, Kay SR. Pineal melatonin in schizophrenia: a review and hypothesis. Schizophr Bull 1990;16:653-62.
13. 13. Lieberman HR. Behavior, sleep and melatonin. J Neural Transm 1986;21(suppl):233-41.
14. 14. Miles A, Philbrick DRS. Melatonin and psychiatry. Biol Psychiatry 1998;23:405-25.
15. 15. Thompson C, Franey C, Arendt J, Checkley SA. A comparison of melatonin secretion in depressed patients and normal subjects. Br J Psychiatry 1988;152:260-5.
16. 16. Frazer A, Brown R, Kocsis J, Caroff S, Amsterdam J, Winokur A, et al. Stokes P-patterns of melatonin rhythms in depression. J Neural Transm 1986;21(suppl):269-90.
17. 17. Demisch K, Demisch L, Nickelsen T, Reith R. The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: increase following fluvoxamine. J Neural Transm 1987;68:257-70.
18. 18. Palazidou E, Skene DJ, Arendt J, Everitt B, Checkley SA. The acute and chronic effects of (+)-and (-)-oxaprotiline upon melatonin secretion in normal subjects. Psychol Med 1992;22:61-7.
19. 19. Nathan PJ, Norman TR, Burrows GD. Nocturnal plasma melatonin concentrations in healthy volunteers: effect of single doses of d-fenfluramine, paroxetine, and ipsapirone. J Pineal Res 1996;21:55-8.
20. 20. Monteleone P, Orazzo C, Natale M, Maj M. Lack of effect of short-term fluoxetine administration on nighttime plasma melatonin levels in healthy subjects. Biol Psychiatry 1994;15:139-42.
21. 21. Skene DJ, Bojkowski CJ, Arendt J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol 1994;37:181-6.
22. 22. Reiter RJ. Neuroendocrinology of melatonin. In: Miles A, Philbrick DRS, Thompson C, editors. Melatonin: clinical perspectives. Oxford: University Press; 1998. p. 1-42.
23. 23. Zatz M, Mullen DA. Norepinephrine, acting via adenylate cyclase, inhibits melatonin output but does not phase-shift the pacemaker in cultured chick pineal cells. Brain Res 1988;450:137-43.
24. 24. Silver H, Barash I, Odnopozov N, Jahjah N, Mizruhin A. Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: evidence for the development of tolerance to selective serotonin reuptake inhibitor. Biol Psychiatry 1996;40:75-7.
25. 25. Demisch K, Demisch L, Bochnik HJ, Nickelsen T, Althoff PH, Schoffling K, et al. Melatonin and cortisol increase after fluvoxamine. Br J Clin Pharmacol 1986;22:620-2.
26. 26. Young IM, Leone RM, Sovell P, Sillmann RE. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin. J Clin Endocrinol Metab 1985;60:114-9.
27. 27. Raynaud F, Mauviard F, Geoffriau M, Claustrat B, Pevet P. Plasma 6-hydroxymelatonin, 6-sulfatoxymelatonin and melatonin kinetics after melatonin administration to rats. Biol Signals 1993;2:359-66.
28. 28. Praast G, Bartsch C, Bartsch H, Mecke D, Lippertt TH. Hepatic hydroxylation of melatonin in the rat is induced by phenobarbital and 7,12-dimethylbenz[a]antracene - implications for cancer etiology. Experientia 1995;51:349-55.
29. 29. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
30. 30. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-21.
31. 31. Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992;38:2082-6.
32. 32. Kashuba AD, Nafziger AN, Kearns GL, Leeder S, Gotschall R, Rocci ML Jr, et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A4 as determined by phenotyping. Clin Pharmacol Ther 1998;64:257-68.
33. 33. Carillo JA, Dahl ML, Svensson JO, Alm C, Rodriguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2. Clin Pharmacol Ther 1996;60:183-90.
34. 34. Spigset O, Granberg K, Hägg S, Norström Å, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997;52:129-33.